ATRA ameliorates fibrosis by suppressing the pro-fibrotic molecule Fra2/AP-1 in systemic sclerosis
In this study, the pro-fibrotic effect of Fra2 in SSc is confirmed. SSc dermal fibroblasts and bleomycin-induced fibrotic tissues of SSc animals exhibit increased levels of Fra2. Inhibition of Fra2 expression in SSc dermal fibroblasts with Fra2 siRNA markedly decreased collagen I expression. ATRA reduced the expressions of Fra2, collagen I, and α-smooth muscle actin(α-SMA) in SSc dermal fibroblasts and bleomycin-induced fibrotic tissues of SSc mice. In addition, chromatin immunoprecipitation and dual-luciferase assays demonstrated that retinoic acid receptor RARα binds to the FRA2 promoter and modulates its transcriptional activity. ATRA decreases collagen I expression both in vivo and in vitro via the reduction of Fra2 expression. This work establishes the rationale for expanding the use of ATRA in the treatment of SSc and indicates that Fra2 can be used as an anti-fibrotic target.PMID:37331293 | DOI:10.1016/j.intimp.2023.110420
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Zixin Pi Jiani Liu Yangfan Xiao Xinglan He Ruixuan Zhu Rui Tang Xiangning Qiu Yi Zhan Zhuotong Zeng Yaqian Shi Rong Xiao Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | Databases & Libraries | Dermatology | Genetics | Scleroderma | Skin | Study | Vitamin A | Vitamins